ABL1 and cancer: Furthermore, combination of dasatinib with different cancer treatments—cisplatin, IR, Olaparib, and CPT11—resulted in significantly reduced cancer cell survival rates compared to single-agent treatments alone (Supplementary Fig. S1C and D), indicating function of ABL1 may be critical to contribute to cell survival by promoting DNA repair.